Some factors of importance in the radiation treatment of malignant melanoma
- PMID: 3085169
- DOI: 10.1016/s0167-8140(86)80048-2
Some factors of importance in the radiation treatment of malignant melanoma
Abstract
The results of radiotherapy in 204 lesions of malignant melanoma in 114 patients were analysed with regard to radiobiological parameters such as total dose, dose per fraction, treatment time, tumour volume and also by various fractionation models. Ninety-seven of 204 lesions showed a complete response (CR) which was persistent in 80. Neither total dose, treatment time nor various modifications of the nominal standard dose (NSD) concept showed any well-defined correlation with response. There was, however, a significant relationship between dose per fraction and response so that high doses per fraction yielded a significantly better response (24% CR for doses less than 4 Gy vs. 57% CR for doses greater than or equal to 4 Gy, p less than 0.001). The lack of influence of treatment time influence allowed an analysis of the data according to the linear-quadratic model yielding an alpha/beta ratio of 2.5 Gy. Using this ratio, an iso-effect for different fractionation schedules could be estimated by the extrapolated total dose (ETD). This was further improved when corrected for the other important parameter which was tumour volume. Thus, an iso-effect formular for malignant melanomas could be calculated as ETDvol = D X ((d + 2.5)/2.5) X M-0.33 where d is total dose and dose per fraction in Gy, respectively and M is mean diameter (cm). The 50% response for ETDvol was found to be 86 Gy. This formular seems to be currently the best way to determine an optimal radiation schedule for effective radiation treatment of malignant melanoma. Treatment of 45 patients with only local or regional disease showed 26 patients who achieved local tumour control with a 56% 3-year survival compared to no survivors among 19 patients in whom the disease could not be controlled locally. This indicated that proper attention should be given to the local treatment of recurrent melanoma since this has important implications for survival. Successful treatment of malignant melanoma may be possible when the special radiobiological features of the disease are taken into account.
Similar articles
-
The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study.Int J Radiat Oncol Biol Phys. 1986 Jun;12(6):867-72. doi: 10.1016/0360-3016(86)90378-0. Int J Radiat Oncol Biol Phys. 1986. PMID: 2424880
-
Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology.Int J Hyperthermia. 1996 Jan-Feb;12(1):3-20. doi: 10.3109/02656739609023685. Int J Hyperthermia. 1996. PMID: 8676005 Clinical Trial.
-
Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience.Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):607-18. doi: 10.1016/s0360-3016(99)00066-8. Int J Radiat Oncol Biol Phys. 1999. PMID: 10348291
-
[Radiotherapy of malignant melanoma of the skin].Praxis (Bern 1994). 2001 Mar 8;90(10):397-402. Praxis (Bern 1994). 2001. PMID: 11305185 Review. German.
-
The role of radiotherapy in the primary management of cutaneous melanoma.Ann Plast Surg. 1992 Jan;28(1):39-44. doi: 10.1097/00000637-199201000-00012. Ann Plast Surg. 1992. PMID: 1379419 Review.
Cited by
-
Adjuvant radiation therapy in metastatic lymph nodes from melanoma.Radiat Oncol. 2011 Feb 6;6:12. doi: 10.1186/1748-717X-6-12. Radiat Oncol. 2011. PMID: 21294913 Free PMC article.
-
2-Methoxyestradiol enhances radiosensitivity in radioresistant melanoma MDA-MB-435R cells by regulating glycolysis via HIF-1α/PDK1 axis.Int J Oncol. 2017 May;50(5):1531-1540. doi: 10.3892/ijo.2017.3924. Epub 2017 Mar 22. Int J Oncol. 2017. PMID: 28339028 Free PMC article.
-
Radiotherapy in the Treatment of Subcutaneous Melanoma.Cancers (Basel). 2021 Nov 22;13(22):5859. doi: 10.3390/cancers13225859. Cancers (Basel). 2021. PMID: 34831017 Free PMC article. Review.
-
18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma.Adv Radiat Oncol. 2017 Feb 24;2(2):204-210. doi: 10.1016/j.adro.2017.02.003. eCollection 2017 Apr-Jun. Adv Radiat Oncol. 2017. PMID: 28740933 Free PMC article.
-
The role of radiation therapy in the management of cutaneous melanoma.Melanoma Manag. 2016 Mar;3(1):61-72. doi: 10.2217/mmt.15.41. Epub 2016 Feb 24. Melanoma Manag. 2016. PMID: 30190873 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical